T. Anh Wartel

2.8k total citations · 1 hit paper
29 papers, 1.1k citations indexed

About

T. Anh Wartel is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Health. According to data from OpenAlex, T. Anh Wartel has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 18 papers in Public Health, Environmental and Occupational Health and 4 papers in Health. Recurrent topics in T. Anh Wartel's work include Mosquito-borne diseases and control (15 papers), Viral Infections and Vectors (9 papers) and Malaria Research and Control (9 papers). T. Anh Wartel is often cited by papers focused on Mosquito-borne diseases and control (15 papers), Viral Infections and Vectors (9 papers) and Malaria Research and Control (9 papers). T. Anh Wartel collaborates with scholars based in South Korea, France and United States. T. Anh Wartel's co-authors include Alain Bouckenooghe, Annick Moureau, Mélanie Saville, Derek Wallace, Pornthep Chanthavanich, Chukiat Sirivichayakul, Kriengsak Limkittikul, Arunee Sabchareon, Nadia Tornieporth and Krisana Pengsaa and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

T. Anh Wartel

28 papers receiving 1.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

2012 636 citations Arunee Sabchareon, Derek Wallace et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Anh Wartel South Korea	15	973	816	97	88	73	29	1.1k
Derek Wallace United States	16	1.2k 1.2×	937 1.1×	112 1.2×	81 0.9×	67 0.9×	32	1.3k
Vianney Tricou United States	15	1.1k 1.2×	1.0k 1.3×	68 0.7×	107 1.2×	66 0.9×	44	1.4k
Annick Moureau France	12	875 0.9×	705 0.9×	95 1.0×	172 2.0×	67 0.9×	29	1.1k
James Whitehorn United Kingdom	15	718 0.7×	527 0.6×	94 1.0×	89 1.0×	37 0.5×	27	912
Wahala M. P. B. Wahala United States	7	1.0k 1.0×	868 1.1×	102 1.1×	108 1.2×	31 0.4×	7	1.1k
Louis Macareo Thailand	16	795 0.8×	621 0.8×	48 0.5×	126 1.4×	138 1.9×	44	1.0k
Alienys Izquierdo Cuba	14	864 0.9×	659 0.8×	73 0.8×	108 1.2×	42 0.6×	21	973
Saravudh Suvannadabba Thailand	10	767 0.8×	647 0.8×	117 1.2×	56 0.6×	47 0.6×	13	911
Akhilesh Chandra Mishra India	14	1.0k 1.0×	1.0k 1.2×	77 0.8×	157 1.8×	25 0.3×	36	1.3k
Beth-Ann Coller United States	17	668 0.7×	771 0.9×	77 0.8×	206 2.3×	56 0.8×	26	1.1k

Countries citing papers authored by T. Anh Wartel

Since Specialization

Citations

This map shows the geographic impact of T. Anh Wartel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Anh Wartel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Anh Wartel more than expected).

Fields of papers citing papers by T. Anh Wartel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Anh Wartel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Anh Wartel. The network helps show where T. Anh Wartel may publish in the future.

Co-authorship network of co-authors of T. Anh Wartel

This figure shows the co-authorship network connecting the top 25 collaborators of T. Anh Wartel. A scholar is included among the top collaborators of T. Anh Wartel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Anh Wartel. T. Anh Wartel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doubell, Anton, Christiane Gerke, Lesley A. Ogilvie, et al.. (2025). Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries. Vaccine. 49. 126771–126771. 1 indexed citations

Shaffer, D. B., et al.. (2025). A landscape analysis of the vaccine ecosystem in Africa: research and development funding, clinical trials, regulation, and manufacturing readiness. The Lancet Global Health. 13(11). e1983–e1990.

Muangnoicharoen, Sant, Saranath Lawpoolsri, Sira Nanthapisal, et al.. (2024). Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial. Vaccine. 42(19). 3999–4010. 2 indexed citations

Auzenbergs, Megan, Kaja Abbas, Gustavo Mendes Lima Santos, et al.. (2024). Chikungunya vaccine development, challenges, and pathway toward public health impact. Vaccine. 42(26). 126483–126483. 10 indexed citations

Muangnoicharoen, Sant, Sira Nanthapisal, Anan Jongkaewwattana, et al.. (2023). Single Ad26.COV2.S Booster Dose Following Two Doses of BBIBP-CorV Vaccine Against SARS-CoV-2 Infection in Adults: Day 28 Results of a Phase 1/2 Open-Label Trial. SSRN Electronic Journal. 1 indexed citations

Poudel, Prakash, Surendra Uranw, Basudha Khanal, et al.. (2023). A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal. Human Vaccines & Immunotherapeutics. 19(1). 2203634–2203634. 4 indexed citations

Muangnoicharoen, Sant, Sira Nanthapisal, Saranath Lawpoolsri, et al.. (2023). Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial. Vaccine. 41(32). 4648–4657. 5 indexed citations

Lynch, Julia, Jacqueline Kyungah Lim, T. Anh Wartel, et al.. (2023). Hepatitis E vaccine—Illuminating the barriers to use. PLoS neglected tropical diseases. 17(1). e0010969–e0010969. 18 indexed citations

Capeding, María Rosario, Birkneh Tilahun Tadesse, Edison Alberto, et al.. (2022). Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose. npj Vaccines. 7(1). 6 indexed citations

10.

Edem, Bassey, Justin R. Ortiz, Anand Kawade, et al.. (2021). Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 39(22). 3028–3036. 5 indexed citations

11.

Chansinghakul, Danaya, Kriengsak Limkittikul, Arunee Sabchareon, et al.. (2019). Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand. Asian Pacific Journal of Tropical Medicine. 12(9). 396–396. 3 indexed citations

12.

Torresi, Joseph, Peter Richmond, Leon Heron, et al.. (2017). Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding. The Journal of Infectious Diseases. 216(7). 834–841. 20 indexed citations

13.

Nealon, Joshua, Anne-Frieda Taurel, Maria Rosario Capeding, et al.. (2016). Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial. PLoS neglected tropical diseases. 10(8). e0004918–e0004918. 37 indexed citations

14.

Plennevaux, Eric, Arunee Sabchareon, Kriengsak Limkittikul, et al.. (2016). Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction. Vaccine. 34(24). 2707–2712. 20 indexed citations

15.

Gailhardou, Sophia, et al.. (2016). Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. PLoS neglected tropical diseases. 10(7). e0004821–e0004821. 37 indexed citations

16.

Frago, Carina, Thelma Laot, Danaya Chansinghakul, et al.. (2016). Integrated analysis of immunogenicity data from 11 dengue vaccine trials across 14 countries at risk for dengue. International Journal of Infectious Diseases. 45. 422–422. 1 indexed citations

17.

Dubey, Anand Prakash, Sharad Agarkhedkar, Jugesh Chhatwal, et al.. (2015). Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. Human Vaccines & Immunotherapeutics. 12(2). 512–518. 18 indexed citations

18.

Wallace, Derek, et al.. (2013). Challenges in the clinical development of a dengue vaccine. Current Opinion in Virology. 3(3). 352–356. 21 indexed citations

19.

Sabchareon, Arunee, Derek Wallace, Chukiat Sirivichayakul, et al.. (2012). Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 380(9853). 1559–1567. 636 indexed citations breakdown →

20.

Leo, Yee‐Sin, Annelies Wilder‐Smith, Sophia Archuleta, et al.. (2012). Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years. Human Vaccines & Immunotherapeutics. 8(9). 1259–1271. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact